Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11503677 | 1.00 | TSHR (0.46) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| SCHEMBL2497118 | 1.00 | — | — | |
| SCHEMBL25918920 | 1.00 | TSHR (0.46) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| SCHEMBL3456820 | 1.00 | TSHR (0.46) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| SCHEMBL17883174 | 1.00 | TSHR (0.46) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| SCHEMBL2493666 | 0.97 | — | — | |
| Ethylene SCHEMBL10656454 | 0.92 | HIF1A (0.43) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| Butane SCHEMBL20548657 | 0.91 | TSHR (0.56) | TSHRHIF1AMAPTCYP1A2CYP2D6 | |
| SCHEMBL543961 | 0.89 | — | — | |
| SCHEMBL11396675 | 0.84 | TSHR (0.34) | TSHRHIF1AMAPTCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906147-B2 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | NANOPROBES, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089836-A1 | superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography | TFRC, FABP1, SCARB1 | TSHR 1345/4885HIF1A 1364/4885MAPT 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.